AMU AMAG Pharmaceuticals Inc.

AMAG Pharmaceuticals to Host Analyst Day on May 22, 2019 in New York

AMAG Pharmaceuticals to Host Analyst Day on May 22, 2019 in New York

WALTHAM, Mass., May 17, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that it will host an Analyst Day for the investment community on Wednesday, May 22, 2019 from 8:30 a.m. to 12:00 p.m. Eastern Time. Members of AMAG’s management team and key opinion leaders will provide updates on the company’s development assets and commercial programs. In-person attendance requires advanced registration. Please contact Linda Lennox at for further information. A live webcast of the event will be accessible through the Investors section of the company’s website at . A replay of the webcast will also be available and archived on the site.

Featured Key Opinion Leader Speakers include:

VyleesiTM (hypoactive sexual desire disorder (HSDD)); PDUFA date June 23, 2019

 
  • Sheryl Kingsberg, PhD, Division Chief of Behavioral Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH 

  • David Portman, MD, Director Emeritus, Columbus Center for Women's Health Research, Adjunct Instructor, Ohio State University, Columbus, OH

  • HSDD patient - fireside chat with HSDD patient and Dr. Sheryl Kingsberg
Ciraparantag (in development as an anticoagulant reversal agent)

 
  • Jack Ansell, MD, Professor of Medicine, Hofstra Northwell School of Medicine, NY

  • Joseph Bledsoe, MD, Department of Emergency Medicine, Intermountain Healthcare, Salt Lake City, UT, Stanford University medical faculty through Intermountain-Stanford collaborative

  • C. Michael Gibson, MD, Interventional cardiologist, cardiovascular researcher, Beth Israel Deaconess Medical Center, Boston, MA

AMAG-423 (in development for the treatment of severe preeclampsia)

 
  • John Barton, MD, Baptist Health Medical Center, Lexington, KY

  • Baha Sibai, MD, Texas Medical Center, Houston, TX

About AMAG

AMAG is a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs. The company does this by leveraging our development and commercial expertise to invest in and grow its pharmaceutical products across a range of therapeutic areas, including women’s health. For additional company information, please visit

AMAG Pharmaceuticals® and "Feraheme® and the logo and designs are registered trademarks of AMAG Pharmaceuticals, Inc. VyleesiTM is a trademark of AMAG Pharmaceuticals, Inc.  Other trademarks referenced in this release are the property of their respective owners.

AMAG Pharmaceuticals Contact:

Linda Lennox

Vice President, Investor Relations

O: 617-498-2846

M: 908-627-3424

EN
17/05/2019

Underlying

AMUAMAG Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AMAG Pharmaceuticals Inc.

 PRESS RELEASE
Free
AMU AMAG Pharmaceut...

AMAG Pharmaceuticals Files Submission in Response To the Food And Drug...

AMAG Pharmaceuticals Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection) WALTHAM, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. has submitted its to the FDA’s Notice of Opportunity for a Hearing (“NOOH”) regarding the Agency’s proposal to withdraw approval for Makena—also referred to as 17-OHPC—the only FDA-approved treatment, along with five generic versions, to reduce preterm birth in women with a singleton pregnancy who have a h...

December 14, 2020 1 EN
 PRESS RELEASE
Free
AMU AMAG Pharmaceut...

AMAG Pharmaceuticals Requests Hearing to Maintain Makena® (Hydroxyprog...

AMAG Pharmaceuticals Requests Hearing to Maintain Makena® (Hydroxyprogesterone Caproate Injection) as a Treatment Option for Clinically Indicated Pregnant Patients WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it has formally requested a public hearing in response to the U.S. Food and Drug Administration’s (FDA) proposal to withdraw its approval of Makena®, the only FDA-approved treatment, along with its equivalent generics, to reduce preterm birth. Makena was approved in 2011, based on the landmark NICHD MFMU trial by . A...

October 14, 2020 1 EN
 PRESS RELEASE
Free
AMU AMAG Pharmaceut...

AMAG Pharmaceuticals Provides Update on FDA’s Proposal Regarding Maken...

AMAG Pharmaceuticals Provides Update on FDA’s Proposal Regarding Makena® (Hydroxyprogesterone Caproate Injection)

October 6, 2020 1 EN
 PRESS RELEASE
Free
AMU AMAG Pharmaceut...

Covis Group Announces Agreement to Acquire AMAG Pharmaceuticals

Covis Group Announces Agreement to Acquire AMAG Pharmaceuticals

October 1, 2020 1 EN
 PRESS RELEASE
Free
AMU AMAG Pharmaceut...

AMAG Pharmaceuticals to Participate in H.C. Wainwright 22nd Annual Glo...

AMAG Pharmaceuticals to Participate in H.C. Wainwright 22nd Annual Global Investment Conference WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Scott Myers, Chief Executive Officer, and Brian Piekos, Chief Financial Officer, will participate in a fireside chat at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 10:30 a.m. Eastern Time. A live audio webcast of the virtual event will be accessible through the Investors section of the company’s website at . A replay of the webcast...

September 9, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch